由吉林省卫生厅、吉林省医药管理局主持召开的新药脑血康口服液新闻发布会于1987年8月14日在北京举行。本品是由吉林省红光制药厂与中国中医研究院西苑医院联合研制的,是卫生部按新药审批办法批准的第3个新药,现已批量生产。脑血康口服液以中药为原料,经科学方法提取精制而成。临床观察表明,对脑缺氧的患者有改善作用,对脑组织损害具有保护作用,并有抑制血小板聚集、抗栓、溶栓作用。动物实验证明,有降压、降血脂作用,能 The press conference for the new drug Naoxuekang Oral Liquid, chaired by the Health Department of Jilin Province and the Jilin Provincial Pharmaceutical Administration, was held in Beijing on August 14, 1987. This product was jointly developed by Jilin Hongguang Pharmaceutical Factory and China Academy of Traditional Chinese Medicine Xiyuan Hospital. It is the third new drug approved by the Ministry of Health under the new drug approval method and is now in mass production. Naoxuekang oral liquid takes traditional Chinese medicine as raw material and is extracted and refined by scientific methods. Clinical observations have shown that patients with cerebral hypoxia have an improving effect, have protective effects on brain tissue damage, and inhibit platelet aggregation, antithrombotic and thrombolytic effects. Animal experiments have shown that there is blood pressure, lipid-lowering effect, energy